-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in T-Cell Acute Lymphocytic Leukemia...
-
Company Insights
Innovation and Patenting activity of NOS SGPS SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of NOS SGPS SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in T-Cell Lymphomas Drug Details: Polatuzumab vedotin (Polivy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Drug Details: Polatuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in Hodgkin Lymphoma (B-Cell Hodgkin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. WU-CART-007 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: WU-CART-007 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Chronic Lymphocytic Leukemia (CLL) Drug Details: Daratumumab...